company background image
5302

Auro Laboratories BSE:530233 Stock Report

Last Price

₹96.95

Market Cap

₹604.2m

7D

3.1%

1Y

-8.2%

Updated

17 May, 2022

Data

Company Financials
530233 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends0/6

530233 Stock Overview

Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India.

Auro Laboratories Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Auro Laboratories
Historical stock prices
Current Share Price₹96.95
52 Week High₹195.00
52 Week Low₹87.00
Beta1
1 Month Change-12.22%
3 Month Change-2.17%
1 Year Change-8.24%
3 Year Change58.03%
5 Year Change131.38%
Change since IPO4,606.31%

Recent News & Updates

Shareholder Returns

530233IN PharmaceuticalsIN Market
7D3.1%-1.6%-3.2%
1Y-8.2%-11.0%9.0%

Return vs Industry: 530233 exceeded the Indian Pharmaceuticals industry which returned -11% over the past year.

Return vs Market: 530233 underperformed the Indian Market which returned 9% over the past year.

Price Volatility

Is 530233's price volatile compared to industry and market?
530233 volatility
530233 Average Weekly Movement6.0%
Pharmaceuticals Industry Average Movement6.9%
Market Average Movement7.2%
10% most volatile stocks in IN Market10.0%
10% least volatile stocks in IN Market4.7%

Stable Share Price: 530233 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 530233's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1989n/aSharat Deorahhttps://www.aurolabs.com

Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India. It offers APIs for various drugs, such as antihistamine, muscle relaxant, diuretic, iron deficiency, anti-diabetic, anti-fungal, anti-ulcer, iodine supplement, anti-malaria, analgesics, antacids, and anti-inflammatory, as well as for other products, including potassium iodide, sodium iodide, and microcrystalline cellulose. The company also provides specialty chemicals comprising guanidine nitrate; dimethyl amine HCl; 2-ethoxy benzoic acid; and 3,4,5 - trimethoxy benzoic acid.

Auro Laboratories Fundamentals Summary

How do Auro Laboratories's earnings and revenue compare to its market cap?
530233 fundamental statistics
Market Cap₹604.24m
Earnings (TTM)₹38.96m
Revenue (TTM)₹465.47m

15.5x

P/E Ratio

1.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
530233 income statement (TTM)
Revenue₹465.47m
Cost of Revenue₹267.46m
Gross Profit₹198.01m
Other Expenses₹159.05m
Earnings₹38.96m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)6.25
Gross Margin42.54%
Net Profit Margin8.37%
Debt/Equity Ratio25.6%

How did 530233 perform over the long term?

See historical performance and comparison

Valuation

Is Auro Laboratories undervalued compared to its fair value and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: 530233 (₹96.95) is trading below our estimate of fair value (₹293.64)

Significantly Below Fair Value: 530233 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 530233 is good value based on its PE Ratio (15.5x) compared to the Indian Pharmaceuticals industry average (21.1x).

PE vs Market: 530233 is good value based on its PE Ratio (15.5x) compared to the Indian market (20.1x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 530233's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 530233 is good value based on its PB Ratio (2x) compared to the IN Pharmaceuticals industry average (2.5x).


Future Growth

How is Auro Laboratories forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


19.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Auro Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Auro Laboratories performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


22.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 530233 has high quality earnings.

Growing Profit Margin: 530233's current net profit margins (8.4%) are lower than last year (12.3%).


Past Earnings Growth Analysis

Earnings Trend: 530233's earnings have grown significantly by 22.5% per year over the past 5 years.

Accelerating Growth: 530233's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 530233 had negative earnings growth (-36.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.4%).


Return on Equity

High ROE: 530233's Return on Equity (12.9%) is considered low.


Financial Health

How is Auro Laboratories's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 530233's short term assets (₹337.0M) exceed its short term liabilities (₹80.3M).

Long Term Liabilities: 530233's short term assets (₹337.0M) exceed its long term liabilities (₹94.3M).


Debt to Equity History and Analysis

Debt Level: 530233 has more cash than its total debt.

Reducing Debt: 530233's debt to equity ratio has reduced from 133.3% to 25.6% over the past 5 years.

Debt Coverage: 530233's debt is well covered by operating cash flow (112.5%).

Interest Coverage: 530233's interest payments on its debt are well covered by EBIT (16.1x coverage).


Balance Sheet


Dividend

What is Auro Laboratories's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 530233's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 530233's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 530233's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 530233's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 530233 has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

15.5yrs

Average board tenure


CEO

Sharat Deorah (71 yo)

no data

Tenure

₹12,000,000

Compensation

Mr. Sharat Sahadeolal Deorah, B.Com. serves as the Managing Director and Executive Chairman of the Board at Auro Laboratories Limited. He serves as Director since May 26, 1989 at Auro Laboratories Limited.


CEO Compensation Analysis

Compensation vs Market: Sharat's total compensation ($USD154.15K) is above average for companies of similar size in the Indian market ($USD38.73K).

Compensation vs Earnings: Sharat's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Board Members

Experienced Board: 530233's board of directors are seasoned and experienced ( 15.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Auro Laboratories Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Auro Laboratories Limited
  • Ticker: 530233
  • Exchange: BSE
  • Founded: 1989
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹604.241m
  • Shares outstanding: 6.23m
  • Website: https://www.aurolabs.com

Number of Employees


Location

  • Auro Laboratories Limited
  • 314, T.V. Industrial Estate
  • 3rd Floor
  • Mumbai
  • Maharashtra
  • 400030
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/17 00:00
End of Day Share Price2022/05/17 00:00
Earnings2021/12/31
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.